All XRAYs
Relevance: High
Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer
Study: Among women with breast cancer, who should have genetic testing for an inherited mutation?
Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)
READ MORE ›
Relevance: Medium-High
Most relevant for: Black women
Study: Insulin resistance linked to differences in breast cancer survival between Black and White women
Black women are more likely to die from breast cancer compared to White women. More Black women have a condition called insulin resistance than White women. This study found that insulin resistance might be one of the reasons that Black women are more likely than White women to die from breast cancer. Additional research is needed to see if lowering insulin levels will improve breast cancer survival in Black women. (07/30/20)
READ MORE ›
Relevance: Medium-High
Most relevant for: Women with breast cancer who have romantic partners
Study: Healthy romantic relationships may decrease stress and inflammation for breast cancer survivors
Satisfying romantic relationships may improve outcomes for women with breast cancer. In a new study, women who were more satisfied with their romantic relationships experienced less stress and lower inflammation. This study suggests that decreasing stress may be beneficial for breast cancer survivors. (7/25/20)
READ MORE ›
Relevance: High
Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)
Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer
The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Study: Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
READ MORE ›
Relevance: High
Most relevant for: Women diagnosed with breast cancer who have a mutation in BRCA1, BRCA2 or TP53
Study: What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?
For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)
READ MORE ›
Relevance: High
Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes
Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)
READ MORE ›
Relevance: High
Most relevant for: People with advanced ovarian cancer who have had a complete or partial response to chemotherapy
Update: New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer
The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)
READ MORE ›
Relevance: High
Most relevant for: Patients with Her2-positive metastatic breast cancer
Update: FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer
The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic triple-negative breast cancer who have received at least two prior lines of treatment
Update: FDA approves new treatment for metastatic triple-negative breast cancer
The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)
READ MORE ›